Adial Pharmaceuticals, Inc. (ADIL) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Charlottesville, VA, アメリカ. 現CEOは Cary John Claiborne.
ADIL を有する IPO日 2018-07-27, 5 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $1.55M.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
